<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753203</url>
  </required_header>
  <id_info>
    <org_study_id>K2020-2011-003</org_study_id>
    <nct_id>NCT04753203</nct_id>
  </id_info>
  <brief_title>Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients</brief_title>
  <acronym>ALCAP</acronym>
  <official_title>A Phase lb/ll, Open Label, Single Arm Study to Assess Efficacy and Safety of Alpelisib and Capecitabine in Patients With PIK3CA Mutant Metastatic Colorectal Cancer Who Failed Two Prior Standard Chemotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator assesses the efficacy and safety of alpelisib and capecitabine in patients&#xD;
      with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase lb To determine maximal tolerated dose (MTD) and recommended phase ll dose (RP2D) of&#xD;
      alpelisib in combination with capecitabine regardless of PIK3CA mutation of any solid tumors&#xD;
&#xD;
      Phase ll To investigate the progression-free survival (PFS)&#xD;
&#xD;
      Conduct the exploratory biomarker analysis for efficacy and resistance of alpelisib plus&#xD;
      capecitabine combination (using collected clinical samples)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A phase lb/ll, open label, single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerable dose</measure>
    <time_frame>up to 6 month</time_frame>
    <description>Maxiaml Tolerable Dose and Recommended Phase 2 Dose of combination Maximal tolerable dose and random phase 2 dose confirmation in Alpelisib with Capecitabine in phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression Free Survival with RP2D dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>Up to 6 month</time_frame>
    <description>Dose limiting toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Objective response rate (by RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time to response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>PIK3CA Gene Mutation</condition>
  <arm_group>
    <arm_group_label>A single arm study with Alpelisib plus Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A phase lb/ll, open label, single arm study with Alpelisib plus Capecitabine in patients with PIK3CA mutant metastatic colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib plus Capecitabine combination</intervention_name>
    <description>Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation</description>
    <arm_group_label>A single arm study with Alpelisib plus Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has signed the Informed Consent Form (ICF) prior to any screening procedures&#xD;
             being performed&#xD;
&#xD;
          2. Age ≥ 19 years old of male and female&#xD;
&#xD;
          3. At each phase of the trial, subjects who meet the following requirements in each phase&#xD;
             will be enrolled.&#xD;
&#xD;
             Phase Ib: Subjects with a histologically-confirmed, advanced/recurrent solid tumor who&#xD;
             have progressed on standard therapy or whose disease does not have established&#xD;
             standard therapy and not limited to PIK3CA mutation Phase II: Subjects with&#xD;
             histologically confirmed, PIK3CA mutated, metastatic colorectal cancer that have&#xD;
             progressed after treatment with two prior standard chemotherapeutic agents with&#xD;
             targeted agents such as cetuximab, bevacizumab, aflibercept (Tissue samples of&#xD;
             colorectal cancer patients must contain just PIK3CA gene alterations. e.g. single&#xD;
             nucleotide variants, small indels, amplifications, structural variation etc. using&#xD;
             targeted panel sequencing.)&#xD;
&#xD;
          4. Patient has evaluable disease as per RECIST 1.1. (Measurable lesions are not mandatory&#xD;
             for study inclusion.)&#xD;
&#xD;
          5. ECOG performance status 0-1&#xD;
&#xD;
          6. Patient has adequate bone marrow and organ function as defined by the following&#xD;
             laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Platelet ≥ 100 x 109/L&#xD;
&#xD;
               -  Serum creatinine ≤ ULN (upper limit of normal) or serum creatinine clearance &gt; 50&#xD;
                  mL/min&#xD;
&#xD;
               -  Total bilirubin: ≤ 1.5 × ULN Subjects with a bile duct obstruction will be&#xD;
                  eligible if they meet the criteria after appropriate bile drainage; Patients with&#xD;
                  Gilbert syndrome should also be included after confirming that the total&#xD;
                  bilirubin level is ≤ 1.5 x ULN in a follow-up screening test.&#xD;
&#xD;
               -  INR ≤1.5&#xD;
&#xD;
               -  Potassium within normal limits, or corrected with supplements&#xD;
&#xD;
               -  Fasting Serum amylase ≤ 2 × ULN&#xD;
&#xD;
               -  Fasting Serum lipase ≤ ULN&#xD;
&#xD;
             Phase Ib: Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ≤ 3 x&#xD;
             ULN (regardless of liver metastases) Phase II: AST and ALT ≤ 3 x ULN if liver&#xD;
             metastases are absent, or AST and ALT ≤ 5 x ULN if liver metastases are present.&#xD;
&#xD;
          7. Adequate cardiac function: QTc ≤480 msec; if QTc exceeds 480 msec, subjects can be&#xD;
             enrolled if the average QTc value is less than 480 msec by measuring 3 times&#xD;
             consecutively in total.&#xD;
&#xD;
          8. The subject is able to swallow and retain oral medication&#xD;
&#xD;
          9. Serum β-HCG test negative within 14 days before the first administration of the study&#xD;
             treatment (women of childbearing potential only).&#xD;
&#xD;
         10. Requirement for contraception must be observed by the subject.&#xD;
&#xD;
         11. Life expectancy of at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has received previous treatment with a PI3K or AKT inhibitor. (Note prior mTOR&#xD;
             inhibitor treatment is allowed.)&#xD;
&#xD;
          2. Patient has received previous capecitabine in metastatic setting.&#xD;
&#xD;
          3. Patient has a known or suspicious hypersensitivity to capecitabine or other products&#xD;
             containing fluorouracil.&#xD;
&#xD;
          4. Any cytotoxic chemotherapy from a previous treatment regimen within 14 days. If the&#xD;
             subject received an investigational drug from another clinical trial, the subject can&#xD;
             be enrolled after 2 weeks of last administration and more than 5 x half-life of the&#xD;
             investigational drug. If monoclonal antibody therapy was given, the subject can be&#xD;
             enrolled after four weeks after the last does.&#xD;
&#xD;
          5. Active central nervous system (CNS) lesions (i.e., those with radiologically unstable&#xD;
             or symptomatic brain lesions). For those who receive radiation or surgical treatment,&#xD;
             the subject can be enrolled if the subject is maintained without steroid therapy and&#xD;
             the evidence of CNS disease progression for more than 4 weeks. However, patients with&#xD;
             leptomeningeal metastases are excluded.&#xD;
&#xD;
          6. Patient has currently documented pneumonitis/interstitial lung disease&#xD;
&#xD;
          7. Patient has not recovered to ≤ grade 1 (except alopecia) from related adverse effects&#xD;
             of any prior anticancer therapy&#xD;
&#xD;
          8. Radiotherapy with a wide field (more than 30% of the bone marrow) of radiation within&#xD;
             4 weeks or radiotherapy with a limited field of radiation for palliation within 2&#xD;
             weeks of the first dose of study treatment.&#xD;
&#xD;
          9. Patient who has undergone major surgery ≤ 4 weeks prior to starting study treatment or&#xD;
             who has not recovered from adverse effects of such procedure.&#xD;
&#xD;
         10. Patient has a clinically significant cardiac disease or impaired cardiac function,&#xD;
             such as:&#xD;
&#xD;
               -  Acute coronary syndrome within the 6 months prior to the initiation of study drug&#xD;
                  (including myocardial infarction or unstable angina, Coronary Artery Bypass Graft&#xD;
                  surgery, percutaneous coronary intervention and stenting)&#xD;
&#xD;
               -  Heart failure ≥ grade 2 by New York Heart Association (NYHA) functional&#xD;
                  classification or that requires treatment&#xD;
&#xD;
               -  Ejection fraction (EF) &lt;50% on multi-gated acquisition (MUGA) scan or&#xD;
                  echocardiography examination. MUGA scan or echocardiography is not required as a&#xD;
                  screening test if there is no current suspicious symptom and past history of&#xD;
                  heart failure.&#xD;
&#xD;
               -  Persistent uncontrolled hypertension as defined by: systolic &gt;160 mmHg or&#xD;
                  diastolic &gt;100 mmHg with or without anti-hypertensive medication. Initiation or&#xD;
                  adjustment of antihypertensive medication(s) is allowed prior to screening.&#xD;
&#xD;
               -  Current or past history of clinically significant cardiac arrhythmia, atrial&#xD;
                  fibrillation, and/or conduction abnormality (e.g. congenital long QT syndrome,&#xD;
                  complete AV block)&#xD;
&#xD;
               -  On screening, inability to determine the QTcF interval on the ECG (i.e.:&#xD;
                  unreadable or not interpretable) or corrected QT (QTcF) &gt;450 msec for males and&#xD;
                  &gt;460 msec for females (using Fridericia's correction). All as determined by&#xD;
                  screening ECG (mean of triplicate ECGs).&#xD;
&#xD;
               -  Any risk factors that prolong QTc or increase the probability of arrhythmia,&#xD;
                  including medication (e.g. heart failure, hypokalemia, congenital long QT&#xD;
                  syndrome, history of Torsades de Pointes)&#xD;
&#xD;
         11. If the subject was diagnosed with diabetes (irrespective of treatment or symptom) or&#xD;
             if the subject has impaired glucose tolerance (with blood glucose of 140-199 mg/dL&#xD;
             after 2 hour oral glucose tolerance test (75g)), previous history of gestational&#xD;
             diabetes, or steroid-induced diabetes.&#xD;
&#xD;
         12. Patients with impaired gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of oral BYL719 (e.g. untreated peptic ulcer&#xD;
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or wide&#xD;
             small bowel resection).&#xD;
&#xD;
         13. History of acute pancreatitis within 1 year of screening or past medical history of&#xD;
             chronic pancreatitis&#xD;
&#xD;
         14. Patient has a known positive serology for human immunodeficiency virus (HIV), active&#xD;
             Hepatitis B, and/or active Hepatitis C infection. Hepatitis B carriers may be enrolled&#xD;
             if prophylactic use of an antiviral agent with minimal interaction with CYP3A4 is&#xD;
             administered to inhibit HBV activation (e.g., entecavir, adefovir)&#xD;
&#xD;
         15. Concomitant medication of strong or moderate inducers or inhibitors of CYP3A4 before&#xD;
             the first dose of study treatment (In this case, if the drug is stopped for more than&#xD;
             1 week and changed to another drug that does not affect CYP3A4, then the subject can&#xD;
             be enrolled.)&#xD;
&#xD;
         16. Inhibitors of BCRP&#xD;
&#xD;
         17. Subjects with unresolved osteonecrosis of the jaw&#xD;
&#xD;
         18. Subject has a history of severe cutaneous reactions like Stevens-Johnson-Syndrome&#xD;
             (SJS), Erythema Multiforme (EM), Toxic Epidermal Necrolysis (TEN), or Drug Reaction&#xD;
             with Eosinophilia and Systemic Symptoms (DRESS).&#xD;
&#xD;
         19. History of other primary cancer. Exceptions are as follows:&#xD;
&#xD;
             - Adequately treated non-melanoma skin cancer (basal cell or squamous cell carcinoma),&#xD;
             curatively treated in situ cancer of the cervix or stage I bladder cancer, completely&#xD;
             resected thyroid cancer without distant metastasis in which all treatment has been&#xD;
             completed (Appropriate wound healing is required prior to clinical trial enrollment)&#xD;
&#xD;
         20. History of allogeneic bone marrow transplantation or organ transplantation&#xD;
&#xD;
         21. As judged by the Investigator, all other symptoms and associated disease for which the&#xD;
             investigator determined that participation in this study is contraindicated (e.g.&#xD;
             Infection/inflammation; severe liver dysfunction; bilateral diffuse interstitial lung&#xD;
             disease; uncontrolled renal disease; unstable heart and lung disease; hemorrhagic&#xD;
             disease; intestinal obstruction; unable to swallow oral pills; social and&#xD;
             psychological problems, etc.)&#xD;
&#xD;
         22. Medical, psychiatric, cognitive, or other conditions that may interfere with the&#xD;
             ability of the subject to understand the subject information, provide the informed&#xD;
             consent, follow the protocol process, or complete the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soohyeon Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Cancer Study Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soohyeon Lee, MD</last_name>
    <phone>+82-10-9948-0263</phone>
    <email>soohyeon_lee@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ah-Reum Lim, MD</last_name>
    <email>ahreumlim@korea.ac.kr</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korean Cancer Study Group</investigator_affiliation>
    <investigator_full_name>SoohyeonLee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

